| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 03/16/2006 | US20060057115 Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| 03/16/2006 | US20060057113 Novel adenoviruses, nucleic acids coding therefor, and use thereof |
| 03/16/2006 | US20060057112 Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances and uses thereof |
| 03/16/2006 | US20060057103 A mutein of IL-15 at least one deletion or substitution in two positions of the amino acid sequence; transplant rejection, autoimmune diseases, inflammatory bowel disease, skin disorders, gatrointestinal disorders, vision defects; antiarthritic, anticarcinogenic, and antidiabetic agents |
| 03/16/2006 | US20060057069 Detection of protein expression in vivo using fluorescent puromycin conjugates |
| 03/16/2006 | US20060054276 Use of an acidic aqueous solution of a bioadhesive polyphenolic protein as an adhesive or coating |
| 03/16/2006 | DE102004036017A1 Growth factors are phosphorylated using amino acids and added phosphate donors for increased effectiveness over a longer time span |
| 03/16/2006 | DE102004035687A1 Isoliertes Photoprotein Aequorin Y89F, sowie dessen Verwendung The isolated photoprotein aequorin Y89F, and its use |
| 03/16/2006 | DE102004035337A1 Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität Variants of the group 1 allergens from Poaceae with reduced allergenicity and preserved T cell reactivity |
| 03/16/2006 | CA2579775A1 Truncated lhrh formulations |
| 03/16/2006 | CA2579656A1 Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| 03/16/2006 | CA2579558A1 Cancer-testis antigens |
| 03/16/2006 | CA2579170A1 Crystal structure of house dust mite allergen der p 1 |
| 03/16/2006 | CA2578097A1 Transport protein used to introduce chemical compounds into nerve cells |
| 03/16/2006 | CA2577823A1 Methods of using death receptor ligands and cd20 antibodies |
| 03/16/2006 | CA2577731A1 Peptide-based body surface reagents for personal care |
| 03/16/2006 | CA2576241A1 Novel proteins which can be used, for example, for the in vitro isolation and prevention of legionella pneumophila infections |
| 03/16/2006 | CA2575753A1 Muteins of fibroblast growth factor 21 |
| 03/15/2006 | EP1635176A1 Method of screening inhibitor by using induction of interleukin 18 production by keratinocyte, method of inducing atopic dermatitis-like symptom and utilization of the same |
| 03/15/2006 | EP1634956A1 Recombinant adeno-associated virus vector for treatment of alzheimer disease |
| 03/15/2006 | EP1634952A2 Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |
| 03/15/2006 | EP1634951A1 Novel protein |
| 03/15/2006 | EP1634949A1 Method for generating activated T-cells and antigen-pulsed antigen-presenting cells |
| 03/15/2006 | EP1634892A2 Composition and methods for the diagnosis of tumours |
| 03/15/2006 | EP1634605A2 Treatment of dyslipidemia in a patient having type 2 diabetes |
| 03/15/2006 | EP1634081A2 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7) |
| 03/15/2006 | EP1633877A1 Flavivirus replicon packaging system |
| 03/15/2006 | EP1633876A2 Methods for the production of insulin in plants |
| 03/15/2006 | EP1633873A1 Bacteria with increased levels of protein secretion, nucleotide sequences coding for a seca protein with increased levels of protein secretion, and method for producing proteins |
| 03/15/2006 | EP1633872A2 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/15/2006 | EP1633870A1 Process |
| 03/15/2006 | EP1633861A1 Crystalline vap-1 and uses thereof |
| 03/15/2006 | EP1633860A2 IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA |
| 03/15/2006 | EP1633859A2 Cell line and uses thereof |
| 03/15/2006 | EP1633858A2 Room temperature storage of organs |
| 03/15/2006 | EP1633853A2 Severe acute respiratory syndrome dna vaccine compositions and methods of use |
| 03/15/2006 | EP1633783A2 Collagen fibrils carrying bioactive heterologous domains and their use in e.g. wound healing |
| 03/15/2006 | EP1633782A2 Novel calcium channels and uses thereof |
| 03/15/2006 | EP1633781A2 Ovomucoid promoters and methods of use |
| 03/15/2006 | EP1633780A2 Control of lactation and peptides therefore |
| 03/15/2006 | EP1633778A1 Poly-gamma-glutamic acid conjugates for eliciting immune responses directed against bacilli |
| 03/15/2006 | EP1633777A2 Chlamydia pneumoniae antigens |
| 03/15/2006 | EP1633775A2 Antigenic peptides of sars coronavirus and uses thereof |
| 03/15/2006 | EP1633772A2 Aav virions with decreased immunoreactivity and uses therefor |
| 03/15/2006 | EP1633769A1 Novel transcription factor, bp1 |
| 03/15/2006 | EP1633398A2 Preparation and application of anti-tumor bifunctional fusion proteins |
| 03/15/2006 | EP1633395A1 Functionally reconstituted viral membranes containing adjuvant |
| 03/15/2006 | EP1633384A2 Stable analogs of peptide and polypeptide therapeutics |
| 03/15/2006 | EP1633383A2 Use of erythropoietin in stroke recovery |
| 03/15/2006 | EP1633382A2 Repeat sequence protein polymer active agent conjugates, methods and uses |
| 03/15/2006 | EP1633381A2 Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity |
| 03/15/2006 | EP1633380A2 Antimicrobial and anticancer lipopeptides |
| 03/15/2006 | EP1633372A2 Vaccines, immunotherapeutics and methods for using the same |
| 03/15/2006 | EP1633317A2 Synthetic chemokine receptor ligands and methods of use thereof |
| 03/15/2006 | EP1633312A2 Influenza hemagglutinin and neuraminidase variants |
| 03/15/2006 | EP1633308A2 Hiv-1 envelope glycoproteins having unusual disulfide structure |
| 03/15/2006 | EP1633304A2 Vascular endothelial growth factor fusion constructs and uses thereof |
| 03/15/2006 | EP1633189A2 Truncated fragments of alpha-synuclein in lewy body disease |
| 03/15/2006 | EP1633184A1 Plant limit dextrinase inhibitor |
| 03/15/2006 | EP1572983A4 Culture chamber for biologicals |
| 03/15/2006 | EP1549757A4 Method of purifying lantibiotics |
| 03/15/2006 | EP1470155B1 Pluripotency determining factor and uses thereof |
| 03/15/2006 | EP1438427A4 Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma |
| 03/15/2006 | EP1370589B1 Rationally designed antibodies |
| 03/15/2006 | EP1364030B1 Supersecretable peptides, processes for their production, and parallel improvement of the secreted form of one or more other polypeptides |
| 03/15/2006 | EP1343879A4 Methods for isolating novel antimicrobial agents from hypermutable mammalian cells |
| 03/15/2006 | EP1342730B1 Fusion protein having the enhanced in vivo activity of erythropoietin |
| 03/15/2006 | EP1294893B1 Modification of hepatitis b core antigen |
| 03/15/2006 | EP1294864B1 Mutated furin polypeptides having improved characteristics |
| 03/15/2006 | EP1233783B9 Hbv/hcv virus-like particle |
| 03/15/2006 | EP1223802B1 Development of an effective gene transfer technique for introducing foreign dna into sperm cells |
| 03/15/2006 | EP1196429B1 Process for the deprotection of protected thiols |
| 03/15/2006 | EP1179059B1 Isolating biological modulators from biodiverse gene fragment libraries |
| 03/15/2006 | EP1162997B1 Staphylococcus antigen and vaccine |
| 03/15/2006 | EP1121600B1 Method and substances for diagnosis and therapy of sepsis and sepsis-like systemic infections |
| 03/15/2006 | EP1068315B1 Therapeutic agent for ngf |
| 03/15/2006 | EP1035863B1 An over-expressing homologous antigen vaccine and a method of making the same |
| 03/15/2006 | EP1007628B1 Transgenic model for heart failure |
| 03/15/2006 | EP0966685B9 Protein fragment complementation assays to detect biomolecular interactions |
| 03/15/2006 | EP0942973B1 Mutants of the lag-3 proteins, products for the expression of these mutants and use |
| 03/15/2006 | EP0939590B1 Nucleic acids for use in gene therapy involving intestinal cell gene expression |
| 03/15/2006 | EP0935658B1 Genetic control of flowering |
| 03/15/2006 | EP0929686B1 Early seed 5' regulatory sequence |
| 03/15/2006 | EP0892849B1 Methods for using the obese gene and its gene product to stimulate hematopoietic development |
| 03/15/2006 | EP0870049B1 Complementary adenoviral vector systems and cell lines |
| 03/15/2006 | EP0846263B1 A method and kit for evaluating the metastatic tendency of tumors |
| 03/15/2006 | EP0797436B1 Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods |
| 03/15/2006 | EP0794960B2 An aglucone isoflavone enriched vegetable protein concentrate and process for producing |
| 03/15/2006 | EP0784477B1 Immunotherapeutic stress protein-peptide complexes against cancer |
| 03/15/2006 | EP0733069B1 Purified primate ctla-8 antigens and related reagents |
| 03/15/2006 | EP0733064B1 Nucleic acids encoding a house dust mite allergen, (der p iii), and uses therefor |
| 03/15/2006 | CN1748030A Primer and probe for detecting vibrio cholerae or vibrio mimicus and detection method using the same |
| 03/15/2006 | CN1748026A Characterization of the gsk-3 beta protein and methods of use thereof |
| 03/15/2006 | CN1747971A Antibody ('11c7') anti nogo a and its pharmaceutical use |
| 03/15/2006 | CN1747970A Antigen/antibody or ligand/receptor glycosylated specificity exchangers |
| 03/15/2006 | CN1747968A Methods for predicting therapeutic response to agents acting on the growth hormone receptor |
| 03/15/2006 | CN1747744A Regeneration and neogenesis of retinal photoreceptor cell using otx2 gene |
| 03/15/2006 | CN1746307A Transcription factor gene of cold-resisting and salt tolerant code regulated lawn plants |
| 03/15/2006 | CN1746306A Recombinant human interferon alpha 4 coded cDNA sequence, production and use thereof |
| 03/15/2006 | CN1746305A Tissue factor pathway inhibitor-2 gene and protein of Banma fish (zTFP-2) |